Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013-Reference-Cited by-同舟云学术

Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013

Published:2014-06-25 Issue:19 Volume:120 Page:3025-3032
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wissing Michel D.¹,Kluetz Paul G.¹,Ning Yang-Min¹,Bull Jonca²,Merenda Christine²,Murgo Anthony J.¹,Pazdur Richard¹

Affiliation:

1. Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation Research; US Food and Drug Administration; Silver Spring Maryland

2. Office of Minority Health; US Food and Drug Administration; Silver Spring Maryland

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference23 articles.

1. Surveillance, Epidemiology, End Results (SEER) Program National Cancer Institute. SEER*Stat fact sheets: prostate http://seer.cancer.gov/statfacts/html/prost.html 2013

2. Cancer statistics for African Americans, 2013;Desantis;CA Cancer J Clin,2013

3. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee;Newman;Cancer,2006

4. Cancer disparities research partnership in Lakota Country: clinical trials, patient services, and community education for the Oglala, Rosebud, and Cheyenne River Sioux tribes;Rogers;Am J Public Health,2005

5. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer;Shavers;Med Care,2004

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer;BJUI Compass;2024-04-02

2. The National Cancer Institute’s Cancer Disparities Research Partnership Program: a unique funding model 20 years later;JNCI: Journal of the National Cancer Institute;2023-09-14

3. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer;BJUI Compass;2023-08-15

4. Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast;The Oncologist;2023-07-07

5. Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study;Cancer Medicine;2022-12-20